Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products

Gene Therapy

Volumn 14, Issue 17, 2007, Pages 1249-1260

  Yuasa, K ^a,b   Yoshimura, M ^a   Urasawa, N ^a   Ohshima, S ^a   Howell, J M ^c   Nakamura, A ^a   Hijikata, T ^b   Miyagoe Suzuki, Y ^a   Takeda, S ^a  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^b MUSASHINO UNIVERSITY   (Japan)

^c MURDOCH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BETA GALACTOSIDASE; CYCLOSPORIN A; DYSTROPHIN; GAMMA INTERFERON; GENE PRODUCT; MITOGENIC AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARVOVIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASSAY; CELL INFILTRATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DOG; DRUG EFFICACY; DRUG SAFETY; DUCHENNE MUSCULAR DYSTROPHY; GENE TRANSFER; GENETIC TRANSDUCTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MUSCLE CELL; MYOTUBE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEROTYPE; SPLEEN CELL; TRANSGENE; VIRAL GENE THERAPY; VIRUS RECOMBINANT; WILD TYPE;

ANIMALS; BASE SEQUENCE; BETA-GALACTOSIDASE; CALMODULIN; CYCLOSPORINE; DEPENDOVIRUS; DOGS; DYSTROPHIN; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAMUSCULAR; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; MOLECULAR SEQUENCE DATA; MUSCLE FIBERS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; MUSCULAR DYSTROPHY, DUCHENNE; PARVOVIRIDAE INFECTIONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPECIES SPECIFICITY; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC; TRANSGENES;

ADENO-ASSOCIATED VIRUS; ANIMALIA; CANIS FAMILIARIS; MURINAE;

EID: 34548138958     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302984     Document Type: Article

References (28)

1. Emery AEH. Duchenne Muscular Dystrophy, 2nd edn. Oxford University Press: Oxford, 1993.
2. Fisher KJ, Jooss K, Alston J, Yang Y, Haecker SE, High K et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 1997; 3: 306-312.
3. Yuasa K, Miyagoe Y, Yamamoto K, Nabeshima Y, Dickson G, Takeda S. Effective restoration of dystrophin-associated proteins in vivo by adenovirus-mediated transfer of trunoated, dystrophin cDNAs. FEBS Lett 1998; 425: 329-336.
4. Harper SQ, Hauser MA, Dellorusso C, Duan D. Crawford RW, Phelps SF et al. Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy. Nat Med 2002; 8: 253-261.
5. Watchko J, O'day T, Wang B, Zhou L, Tang Y, Li J et al. Adeno-associated virus vector mediated minidystrophin gene therapy improves dystrophic muscle contractile function in mdx mice. Hum Gene Ther 2002; 13: 1451-1460.
6. Fabb SA, Wells DJ, Serpente P, Dickson G, Adeno-associated virus vector gene transfer and sarcolemmal expression of a 144 kDa micro-dystrophin effectively restores the dystrophin-associated protein complex and inhibits myofibre degeneration in nude/mdx mices. Hum Mol Genet 2002; 11: 733-741.
7. Sakamoto M. Yuasa K, Yoshimura M, Yokota T, Ikemoto, T, Suzuki M et al. Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene. Biochem Biophys Res Commun 2002; 293: 1265-1272.
8. Yuasa K, Sakamoto M, Miyagoe-Suzuki Y, Tanouchi A, Yamamoto H, Li J et al. Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product. Gene Therapy 2002; 9: 1576-1588.
9. Yoshimura M, Sakamoto M, Ikemoto M, Mochizuki Y, Yuasa K, Miyagoe-Suzuki Y et al. AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype. Mol Ther 2004; 10: 821-828.
10. J). Exp Animals 2003; 52: 93-97.
11. J. Acta Myologica 2005; 24: 145-154.
12. Valentine BA, Cooper BJ, Cummings JF, De Lahunta. A. Canine X-linked muscular dystrophy: Morphologic lesions. J Neurol Sci 1990; 97 1-23.
13. Manno CS, Arruda VR, Pierce GF, Glader B, Ragni M, Rasko J et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342-347.
14. Fisher KJ, Gao GP, Weitzman MD, DeMatteo R, Burda JF, Wilson JM. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol 1996; 70: 520-532.
15. Herzog RW, Yang EY, Couto LB, Hagstrom JN, Elwell D, Fields PA et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 1999; 5: 56-63.
16. Fields PA, Kowalczyk DW, Arruda VR, Armstrong E, Mccleland ML, Hagstrom JN et al. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. Mol Ther 2000, 1: 225-235.
17. Herzog RW, Mount JD, Arruda VR, High KA, Lothrop Jr CD. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. Mol Ther 2001; 4: 192-200.
18. Herzog RW, Fields PA, Arruda VR, Brubaker JO, Armstrong E, Mcclintock D et al. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Hum Gene Ther 2002, 13: 1281-1291.
19. Arruda, VR, Stedman HH, Nichols TC, Haskins ME, Nicholson M, Herzog RW et al. Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. Blood 2005, 105 3458-3464
20. Zhang Y, chirmule N, Gao G, Wilson J. CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo role of immature dendritic cells. J. Virol 2000; 74: 8003-8010.
21. Wang Z, Zhu T, Qiao C, Zhou L, Wang B, Zhang J et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 2005; 23: 321-328.
22. Inagaki K, Fuess S, Storm TA, Gibson GA, Mctiernan CF, Kay MA et al. Robust systemic transduction with AAV9 vectors in mice: Efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 2006; 14: 45-53.
23. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the 'absence of helper adenovirus. J Virol 1998; 72: 2224-2232.
24. Snyder R, Xiao X, Samulski RJ. Production of recombinant adeno-associated viral vectors. In: Dracopoli N, Haines J, Korf B, Morton C, Seidman C, Seidman JG, Smith D (eds). Current Protocols in Human Genetics. John Wiley & Sons Ltd: New York, 1996, pp 12.1.1-12.2.23.
25. Auricchio A, Hildinger M, O'connor E, Gao GP, Wilson JM. Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum Gene Ther 2001; 12: 71-76.
26. Howell JM, Fletcher S, Kakulas BA, O'hara M, Lochmuller H, Karpati G. Use of the dog model for Duchenne muscular dystrophy in gene therapy trials. Neuromuscul Disord 1997; 7: 325-328.
27. Howell JM, Lochmuller H, O'hara A, Fletcher S, Kakulas BA, Massie B et al. High-level dystrophin expression after adeno-virus-mediated dystrophin minigene transfer to skeletal muscle of dystrophic dogs: prolongation of expression with immuno-suppression. Hum Gene Ther 1998; 9: 629-634.
28. Rando TA, Blau HM. Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy. J Cell Biol 1994; 125: 1275-1287.